Height prognosis of children with true precocious puberty and growth hormone deficiency: Effect of combination therapy with gonadotropin releasing hormone agonist and growth hormone
- 31 May 1992
- journal article
- research article
- Published by Elsevier BV in The Journal of Pediatrics
- Vol. 120 (5), 709-715
- https://doi.org/10.1016/s0022-3476(05)80232-x
Abstract
We evaluated height prognosis and therapeutic efficacy of long-term, combination therapy with gonadotropin releasing-hormone agonist and growth hormone (GH) in five children (three girls) with coexistent precocious puberty and GH deficiency. Their clinical characteristics and growth response were compared with those of 12 girls with idiopathic true precocious puberty and eight prepubertal GH-deficient children (one girl). Precocious GH-deficient subjects were older than the precocious GH-sufficient children (9.5 +/- 1.8 years vs 6.5 +/- 1.3 years; mean +/- SD), but bone ages were comparable (12 +/- 3.7 years vs 10 +/- 0.9 years); their chronologic age was similar to that of the prepubertal GH-deficient children (9.6 +/- 2.1 years), but bone age was significantly more advanced (6.9 +/- 2.3 years). The mean height velocity of the prepubertal GH-deficient children (3.8 +/- 1.5 cm/yr) was lower than that of the precocious GH-deficient subjects (6.7 +/- 1.6 cm/yr) and the precocious GH-sufficient children (9.5 +/- 2.9 cm/yr). Baseline adult height prediction z scores were significantly lower in the precocious GH-deficient children (-3.7 +/- 1.0) than in either the precocious GH-sufficient children (-2.2 +/- 1.0) or the prepubertal GH-deficient subjects (-1.5 +/- 0.8). During therapy with gonadotropin releasing-hormone agonist, growth rates slowed to an average of 3.7 cm/yr in the precocious GH-deficient children but increased after the addition of GH to 7.4 cm during the first year of combination therapy. After 2 to 3 years of combination therapy, height predictions increased an average of 10 cm, compared with an increase of 2.8 cm in the precocious GH-sufficient group treated with gonadotropin releasing-hormone agonist alone. We conclude that combination treatment with gonadotropin releasing-hormone agonist and GH improves the height prognosis of children with coexistent true precocious puberty and GH deficiency, but falls short of achieving normal adult height potential.Keywords
This publication has 21 references indexed in Scilit:
- Preserving adult height potential in girls with idiopathic true precocious pubertyThe Journal of Pediatrics, 1990
- Idiopathic short stature: Results of a one-year controlled study of human growth hormone treatmentThe Journal of Pediatrics, 1989
- Growth hormone deficiency impedes the rise in plasma insulin-like growth factor I levels associated with precocious pubertyThe Journal of Pediatrics, 1989
- Six-year results of luteinizing hormone releasing hormone (LHRH) agonist treatment in children with LHRH-dependent precocious pubertyThe Journal of Pediatrics, 1989
- Effects of leuprolide in the treatment of central precocious pubertyThe Journal of Pediatrics, 1989
- Dose-response Relationship in the Treatment of Hypopituitary Children with Human Growth Hormone: a Retrospective SurveyActa Paediatrica, 1987
- Advances in diagnosis and treatment of short stature, with special reference to the role of growth hormoneThe Journal of Pediatrics, 1984
- Skeletal age predictionThe Journal of Pediatrics, 1971
- Precocious PubertyAmerican Journal of Diseases of Children, 1968
- Tables for predicting adult height from skeletal age: Revised for use with the greulich-pyle hand standardsThe Journal of Pediatrics, 1952